The HER2 overexpression rate was 21.2% for patients with gastric adenocarcinoma, and HER2 overexpression was predominantly seen in males, well- and moderately differentiated adenocarcinomas, intestinal type according to the Lauren classification, and low T stage. This evidence concerns the gene ERBB2 and adenocarcinoma.